Carfilzomib for relapsed and refractory multiple myeloma

Although the prognosis of multiple myeloma (MM) patients has dramatically improved during recent years, virtually all patients eventually develop relapsed refractory disease. Several new therapeutics have been developed in the last few years, including carfilzomib, a second-generation proteasome inh...

Descripción completa

Detalles Bibliográficos
Autores principales: Groen, K, van de Donk, NWCJ, Stege, CAM, Zweegman, S, Nijhof, IS
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450182/
https://www.ncbi.nlm.nih.gov/pubmed/31037034
http://dx.doi.org/10.2147/CMAR.S150653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450182/
https://www.ncbi.nlm.nih.gov/pubmed/31037034
http://dx.doi.org/10.2147/CMAR.S150653

Ejemplares similares